Surinabant

Drugbox
IUPAC_name = 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide


CAS_number = 288104-79-0
ATC_prefix =
ATC_suffix =
PubChem = 9849616
DrugBank =
chemical_formula = |C=23|H=23|Br=1|Cl=2|N=4|O=1
molecular_weight = 522.264 g/mol
smiles = Clc2cc(Cl)ccc2-n1nc(C(=O)NN4CCCCC4)c(CC)c1-c3ccc(Br)cc3
bioavailability =
protein_bound =
metabolism =
elimination_half-life =
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category=
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status =
routes_of_administration =

Surinabant (SR-147,778) is a cannabinoid receptor type 1 antagonist developed by Sanofi-Aventis. [Rinaldi-Carmona M, Barth F, Congy C, Martinez S, Oustric D, Pério A, Poncelet M, Maruani J, Arnone M, Finance O, Soubrié P, Le Fur G. SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide] , a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization. "Journal of Pharmacology and Experimental Therapeutics". 2004 Sep;310(3):905-14. PMID 15131245] It is being investigated as a potential treatment for nicotine addiction, to assist smoking cessation. It may also be developed as an anorectic drug to assist with weight loss, however there are already several CB₁ antagonists or inverse agonists on the market or under development for this application, [Doggrell SA. Will the new CB1 cannabinoid receptor antagonist SR-147778 have advantages over rimonabant? "Expert Opinion on Investigational Drugs". 2005 Mar;14(3):339-42. PMID 15833065] so surinabant is at present mainly being developed as an anti-smoking drug, [Lamota L, Bermudez-Silva FJ, Marco EM, Llorente R, Gallego A, Rodríguez de Fonseca F, Viveros MP. Effects of adolescent nicotine and SR 147778 (Surinabant) administration on food intake, somatic growth and metabolic parameters in rats. "Neuropharmacology". 2008 Jan;54(1):194-205. PMID 17720206] with possible application in the treatment of other addictive disorders such as alcoholism. [Gessa GL, Serra S, Vacca G, Carai MA, Colombo G. Suppressing effect of the cannabinoid CB1 receptor antagonist, SR147778, on alcohol intake and motivational properties of alcohol in alcohol-preferring sP rats. "Alcohol and Alcoholism". 2005 Jan-Feb;40(1):46-53. PMID 15582988] [Lallemand F, De Witte P. SR147778, a CB1 cannabinoid receptor antagonist, suppresses ethanol preference in chronically alcoholized Wistar rats. "Alcohol". 2006 Jul;39(3):125-34. PMID 17127132] Other potential applications such as treatment of ADHD have also been proposed. [Louis C, Terranova JP, Decobert M, Bizot JC, Francon D, Alonso R, Cohen C, Griebel G. Surinabant, a new CB1 receptor antagonist, displays efficacy in animal models of attention deficit/hyperactivity disorder. "Behavioural Pharmacology" 2005; 16:S42.]

References